Colorectal Cancer | Specialty

Grothey Gives Insight on Nintedanib, Immunotherapy Activity in CRC

July 28th 2016

Axel Grothey, MD, discusses both the LUME-1 and LUME-2 trials, the differences between left and right tumors in colorectal cancer, and how that information could potentially be used in diagnosis and treatment.

Dr. Van Cutsem on Regorafenib for Patients With Colorectal Cancer

July 25th 2016

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses regorafenib (Stivarga) as a treatment for patients with colorectal cancer.

Dr. Venook on Evolving Treatment Strategies in CRC

July 22nd 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how treatment strategies have evolved for patients with colorectal cancer.

Dr. Udit Verma on Managing Regorafenib Side Effects in CRC

July 22nd 2016

Dr. Bekaii-Saab on Dosing Strategies With Regorafenib in CRC

July 22nd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses dosing strategies with regorafenib (Stivarga) in patients with colorectal cancer (CRC).

Dr. Pietrantonio on Nomogram to Predict Survival Rates in CRC

July 20th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses findings of a clinical trial examining a nomogram used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Possible Biomarker Could Determine Risk of Colon Cancer Recurrence

July 15th 2016

A liquid biopsy test of circulating tumor DNA for residual disease may be able to determine the risk of recurrence for patients with stage II colon cancer beyond radiologic tests and clinicopathological risk features.

Dr. Heinemann on Surrogate Markers Beyond PFS in Patients With CRC

July 14th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses surrogate markers aside from progression-free survival (PFS) in studying patients with colorectal cancer (CRC).

Immunotherapy Potential Continues to Grow in Gastric Cancers

July 14th 2016

Hendrik-Tobias Arkenau, MD, PhD, discusses the significance of the JAVELIN results for gastrointestinal cancer, the potential for CTLA-4 and PD-1/PD-L1 combinations, and the promise of pembrolizumab (Keytruda) in colorectal cancer.

Dr. Sharma on Results of SIRFLOX Study for CRC

July 14th 2016

Navesh K. Sharma, DO, PhD, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study, which examined the addition of Yttrium-90 (Y-90) resin microspheres (SIR-Spheres) to standard frontline FOLFOX-based chemotherapy with or without bevacizumab for patients with liver metastatic colorectal cancer (CRC).

A Closer Look at Tumor Location Analyses in Colon Cancer

July 14th 2016

Tumor Locations in CRC

July 14th 2016

A Closer Look at FIRE-3 and CALGB/SWOG 80405

July 14th 2016

First-line Targeted Therapies in Metastatic CRC

July 14th 2016

Practical Application of Molecular Testing in CRC

July 14th 2016

Personalized Medicine in Colorectal Cancer

July 14th 2016

Dr. Kanwal Raghav on the Biology of HER2 Gene Amplification in mCRC

July 13th 2016

Survival Outcomes Affected by Tumor Location in KRAS Wild-Type mCRC

July 12th 2016

The debate between the phase III CALGB/SWOG 80405 and FIRE-3 studies has been settled, as findings of a retrospective analysis of 80405 show that tumor location is significant in determining survival outcomes for patients with KRAS wild-type metastatic colorectal cancer.

Referring Patients with Colorectal Cancer to Clinical Trials

July 12th 2016

Role of TAS-102 (Trifluridine/tipiracil) in Advanced Colorectal Cancer

July 12th 2016